PAN India Service 

WHO Certified

I. FDA Approves Encorafenib and Binimetinib in Combination for Unresectable or Metastatic Melanoma with BRAF Mutations. II. FDA Approves Avatrombopag for Thrombocytopenia in Adults with Chronic Liver Disease.

I. FDA Approves Encorafenib and Binimetinib in Combination for Unresectable or Metastatic Melanoma with BRAF Mutations. II. FDA Approves Avatrombopag for Thrombocytopenia in Adults with Chronic Liver Disease.

Read more I. FDA Approves Encorafenib and Binimetinib in Combination for Unresectable or Metastatic Melanoma with BRAF Mutations. II. FDA Approves Avatrombopag for Thrombocytopenia in Adults with Chronic Liver Disease.